Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron in Advanced Renal Cell Carcinoma
NCT00045279Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2002
- Primary completion
- Sep 2005
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00045279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045279.